{"hands_on_practices": [{"introduction": "A hallmark of T cell activation is a dramatic increase in glycolysis, which fuels the immense biosynthetic and energetic demands of proliferation and effector function. This exercise uses a classic biochemical model, Michaelis-Menten kinetics, to quantitatively explore how a limited supply of glucose can directly constrain adenosine triphosphate ($ATP$) production and, consequently, vital functions like cytokine secretion. By working through this scenario, you will build foundational skills in applying kinetic models to understand how the metabolic environment, such as a nutrient-poor tumor, can shape T cell behavior [@problem_id:2868681].", "problem": "Activated T cells rapidly increase aerobic glycolysis to support adenosine triphosphate (ATP) generation and anabolic needs that enable effector functions such as cytokine secretion. Consider an activated T cell for which extracellular glucose is the limiting substrate for glycolysis. Use the following modeling assumptions grounded in well-tested biochemical kinetics and immunometabolic observations.\n\n1. Glucose uptake is the rate-limiting input to glycolysis and follows Michaelis–Menten kinetics with respect to extracellular glucose concentration, so that the glucose uptake rate is $v_{\\text{glc}}([G]) = V_{\\max}\\,\\dfrac{[G]}{K_{m} + [G]}$, where $[G]$ is extracellular glucose. Take $K_{m} = 3.0$ mM, and treat $V_{\\max}$ as an unknown constant that may cancel in ratios.\n\n2. Net ATP yield from glycolysis is $Y_{\\text{ATP}} = 2$ ATP per glucose consumed, so the glycolytic ATP production rate is $J_{\\text{glyc}}([G]) = Y_{\\text{ATP}}\\,v_{\\text{glc}}([G])$.\n\n3. Cytokine secretion rate $R$ is limited by glycolytic ATP supply and follows a saturable, first-order dependence on $J_{\\text{glyc}}$ of the form $R(J_{\\text{glyc}}) = R_{\\max}\\,\\dfrac{J_{\\text{glyc}}}{J_{\\text{glyc}} + J_{50}}$, where $J_{50}$ is the glycolytic ATP production rate that yields half-maximal cytokine secretion. Assume $J_{50}$ equals one-half of the maximal glycolytic ATP production rate, i.e., $J_{50} = \\dfrac{1}{2}\\,J_{\\text{glyc}}^{\\max}$, with $J_{\\text{glyc}}^{\\max} = Y_{\\text{ATP}}\\,V_{\\max}$.\n\n4. Ignore any changes in oxidative phosphorylation or other pathways; treat cytokine secretion as controlled by glycolytic ATP supply alone under these conditions.\n\nExtracellular glucose is decreased from $5$ mM to $0.5$ mM. Compute the impact of this change on:\n- the steady-state glycolytic ATP production rate, expressed as the ratio $\\dfrac{J_{\\text{glyc}}(0.5\\ \\text{mM})}{J_{\\text{glyc}}(5\\ \\text{mM})}$, and\n- the steady-state cytokine secretion rate, expressed as the ratio $\\dfrac{R(0.5\\ \\text{mM})}{R(5\\ \\text{mM})}$.\n\nExpress your final answer as a row matrix of the two ratios in this order: first the glycolytic ATP ratio, then the cytokine secretion ratio. Round both entries to four significant figures. Do not include units in the final numerical answer.", "solution": "The problem asks for the computation of two ratios related to T cell metabolism when the extracellular glucose concentration changes. The problem statement is scientifically grounded, well-posed, and provides all necessary information to derive a unique solution. The model, while a simplification of complex biological reality, is based on standard biochemical kinetic formalisms (Michaelis-Menten kinetics) and established principles of immunometabolism. The constants and concentrations are within a physiologically plausible range. Therefore, the problem is valid and a solution can be constructed.\n\nFirst, we calculate the ratio of the glycolytic ATP production rates, $\\dfrac{J_{\\text{glyc}}(0.5\\ \\text{mM})}{J_{\\text{glyc}}(5\\ \\text{mM})}$.\nThe glycolytic ATP production rate, $J_{\\text{glyc}}$, is given as a function of the extracellular glucose concentration, $[G]$:\n$$ J_{\\text{glyc}}([G]) = Y_{\\text{ATP}}\\,v_{\\text{glc}}([G]) $$\nwhere $Y_{\\text{ATP}} = 2$ is the ATP yield per glucose molecule, and the glucose uptake rate $v_{\\text{glc}}([G])$ follows Michaelis-Menten kinetics:\n$$ v_{\\text{glc}}([G]) = V_{\\max}\\,\\dfrac{[G]}{K_{m} + [G]} $$\nCombining these gives the full expression for the ATP production rate:\n$$ J_{\\text{glyc}}([G]) = Y_{\\text{ATP}}\\,V_{\\max}\\,\\dfrac{[G]}{K_{m} + [G]} $$\nWe need to compute the ratio of this rate at two different glucose concentrations, $[G]_1 = 5$ mM and $[G]_2 = 0.5$ mM. The ratio is given by:\n$$ \\frac{J_{\\text{glyc}}([G]_2)}{J_{\\text{glyc}}([G]_1)} = \\frac{Y_{\\text{ATP}}\\,V_{\\max}\\,\\dfrac{[G]_2}{K_{m} + [G]_2}}{Y_{\\text{ATP}}\\,V_{\\max}\\,\\dfrac{[G]_1}{K_{m} + [G]_1}} $$\nThe constants $Y_{\\text{ATP}}$ and $V_{\\max}$ cancel out, yielding:\n$$ \\frac{J_{\\text{glyc}}([G]_2)}{J_{\\text{glyc}}([G]_1)} = \\frac{\\dfrac{[G]_2}{K_{m} + [G]_2}}{\\dfrac{[G]_1}{K_{m} + [G]_1}} = \\frac{[G]_2}{[G]_1} \\cdot \\frac{K_{m} + [G]_1}{K_{m} + [G]_2} $$\nSubstituting the given values, $K_{m} = 3.0$ mM, $[G]_1 = 5$ mM, and $[G]_2 = 0.5$ mM:\n$$ \\frac{J_{\\text{glyc}}(0.5\\ \\text{mM})}{J_{\\text{glyc}}(5\\ \\text{mM})} = \\frac{0.5}{5} \\cdot \\frac{3.0 + 5}{3.0 + 0.5} = 0.1 \\cdot \\frac{8.0}{3.5} = \\frac{0.8}{3.5} = \\frac{8}{35} $$\nAs a decimal, this ratio is approximately $0.2285714$. Rounding to four significant figures gives $0.2286$.\n\nSecond, we calculate the ratio of the cytokine secretion rates, $\\dfrac{R(0.5\\ \\text{mM})}{R(5\\ \\text{mM})}$.\nThe cytokine secretion rate, $R$, is given as a function of the glycolytic ATP production rate, $J_{\\text{glyc}}$:\n$$ R(J_{\\text{glyc}}) = R_{\\max}\\,\\dfrac{J_{\\text{glyc}}}{J_{\\text{glyc}} + J_{50}} $$\nWe are given that $J_{50} = \\dfrac{1}{2}\\,J_{\\text{glyc}}^{\\max}$, where $J_{\\text{glyc}}^{\\max} = Y_{\\text{ATP}}\\,V_{\\max}$. This means $J_{50} = \\dfrac{1}{2}\\,Y_{\\text{ATP}}\\,V_{\\max}$.\nTo express $R$ as a function of $[G]$, we substitute the expression for $J_{\\text{glyc}}([G])$:\n$$ R([G]) = R_{\\max}\\,\\dfrac{Y_{\\text{ATP}}\\,V_{\\max}\\,\\dfrac{[G]}{K_{m} + [G]}}{Y_{\\text{ATP}}\\,V_{\\max}\\,\\dfrac{[G]}{K_{m} + [G]} + \\dfrac{1}{2}\\,Y_{\\text{ATP}}\\,V_{\\max}} $$\nThe term $Y_{\\text{ATP}}\\,V_{\\max}$ is a common factor in the denominator's terms and also appears in the numerator, so it cancels out:\n$$ R([G]) = R_{\\max}\\,\\dfrac{\\dfrac{[G]}{K_{m} + [G]}}{\\dfrac{[G]}{K_{m} + [G]} + \\dfrac{1}{2}} $$\nTo simplify this expression, we multiply the numerator and denominator by $2(K_{m} + [G])$:\n$$ R([G]) = R_{\\max}\\,\\dfrac{2[G]}{2[G] + (K_{m} + [G])} = R_{\\max}\\,\\dfrac{2[G]}{3[G] + K_{m}} $$\nNow we can compute the ratio of secretion rates at $[G]_1 = 5$ mM and $[G]_2 = 0.5$ mM:\n$$ \\frac{R([G]_2)}{R([G]_1)} = \\frac{R_{\\max}\\,\\dfrac{2[G]_2}{3[G]_2 + K_{m}}}{R_{\\max}\\,\\dfrac{2[G]_1}{3[G]_1 + K_{m}}} $$\nThe constant $R_{\\max}$ and the factor of $2$ cancel:\n$$ \\frac{R([G]_2)}{R([G]_1)} = \\frac{\\dfrac{[G]_2}{3[G]_2 + K_{m}}}{\\dfrac{[G]_1}{3[G]_1 + K_{m}}} = \\frac{[G]_2}{[G]_1} \\cdot \\frac{3[G]_1 + K_{m}}{3[G]_2 + K_{m}} $$\nSubstituting the given values, $K_{m} = 3.0$ mM, $[G]_1 = 5$ mM, and $[G]_2 = 0.5$ mM:\n$$ \\frac{R(0.5\\ \\text{mM})}{R(5\\ \\text{mM})} = \\frac{0.5}{5} \\cdot \\frac{3(5) + 3.0}{3(0.5) + 3.0} = 0.1 \\cdot \\frac{15.0 + 3.0}{1.5 + 3.0} = 0.1 \\cdot \\frac{18.0}{4.5} $$\nSince $\\frac{18.0}{4.5} = 4$, the ratio is:\n$$ \\frac{R(0.5\\ \\text{mM})}{R(5\\ \\text{mM})} = 0.1 \\cdot 4 = 0.4 $$\nExpressed to four significant figures, this is $0.4000$.\n\nThe two required ratios are $0.2286$ for the glycolytic ATP production rate and $0.4000$ for the cytokine secretion rate.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.2286 & 0.4000\n\\end{pmatrix}\n}\n$$", "id": "2868681"}, {"introduction": "To characterize the metabolic state of T cells, researchers rely on powerful experimental techniques. This problem delves into the analysis of data from a Seahorse XF mitochondrial stress test, a cornerstone assay in immunometabolism research. By understanding the mechanism of specific mitochondrial inhibitors, you will learn to parse the composite oxygen consumption rate ($OCR$) into its key components, including basal respiration, $ATP$-linked respiration, and spare respiratory capacity. This practice provides direct, hands-on experience in translating raw experimental data into meaningful bioenergetic parameters that define a T cell's metabolic phenotype and potential [@problem_id:2868684].", "problem": "In human memory T cells, activation state and differentiation correlate with shifts in bioenergetic partitioning between glycolysis and mitochondrial oxidative phosphorylation. A standard mitochondrial stress test uses sequential perturbations to dissect contributions to the oxygen consumption rate (OCR). The following widely accepted mechanistic facts form the basis for quantitative decomposition of OCR: (i) oligomycin inhibits adenosine triphosphate (ATP) synthase, dropping OCR to a level reflecting proton leak plus non-mitochondrial oxygen consumption; (ii) carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) uncouples the proton gradient, revealing the maximal electron transport chain capacity; and (iii) rotenone and antimycin A inhibit mitochondrial complexes I and III, revealing non-mitochondrial oxygen consumption.\n\nYou are provided oxygen consumption rate measurements for purified human memory T cells during a Seahorse assay. Values are already normalized per well to $10^{5}$ cells and are reported in $\\mathrm{pmol\\ O_{2}\\ min^{-1}\\ per\\ }10^{5}\\ \\mathrm{cells}$. For each phase, use the average of the last three steady cycles.\n\n- Basal (pre-injection) OCR: $128$, $132$, $130$.\n- After oligomycin injection: $78$, $80$, $79$.\n- After FCCP injection: $210$, $205$, $208$.\n- After rotenone/antimycin A injection: $20$, $19$, $21$.\n\nUsing only the mechanistic facts above and first principles of how each perturbation isolates specific OCR components, compute:\n- Basal mitochondrial respiration.\n- ATP-linked respiration.\n- Spare respiratory capacity.\n\nReport your answer as a row matrix in the order $[\\text{basal mitochondrial respiration},\\ \\text{ATP-linked respiration},\\ \\text{spare respiratory capacity}]$, in the unit $\\mathrm{pmol\\ O_{2}\\ min^{-1}\\ per\\ }10^{5}\\ \\mathrm{cells}$, and round each entry to three significant figures in scientific notation. Do not include units in your final boxed answer.", "solution": "We start from the mechanistic definitions and how inhibitor responses isolate OCR components:\n\n- Oligomycin inhibits adenosine triphosphate (ATP) synthase, so OCR after oligomycin reflects proton leak plus non-mitochondrial oxygen consumption. The difference between basal OCR and oligomycin OCR therefore reflects ATP-linked respiration, because the non-mitochondrial component is present in both and cancels on subtraction.\n\n- Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) uncouples oxidative phosphorylation, collapsing the proton gradient to drive maximal electron transport chain flux. The OCR after FCCP (corrected for non-mitochondrial oxygen consumption) is the maximal mitochondrial respiration.\n\n- Rotenone/antimycin A inhibit complexes I and III, respectively, leaving only non-mitochondrial oxygen consumption; this provides the non-mitochondrial OCR to subtract from basal and FCCP phases when computing mitochondrial components.\n\nLet the phase means be:\n- Basal mean $B = \\dfrac{128 + 132 + 130}{3}$.\n- Oligomycin mean $O = \\dfrac{78 + 80 + 79}{3}$.\n- FCCP mean $F = \\dfrac{210 + 205 + 208}{3}$.\n- Rotenone/antimycin A mean (non-mitochondrial) $N = \\dfrac{20 + 19 + 21}{3}$.\n\nCompute the means:\n- $B = \\dfrac{390}{3} = 130$.\n- $O = \\dfrac{237}{3} = 79$.\n- $F = \\dfrac{623}{3} = 207.\\overline{6}$.\n- $N = \\dfrac{60}{3} = 20$.\n\nNow derive the components:\n\n1. Basal mitochondrial respiration equals basal OCR corrected for non-mitochondrial oxygen consumption:\n$$\n\\text{Basal mitochondrial respiration} = B - N = 130 - 20 = 110.\n$$\n\n2. ATP-linked respiration equals the drop in OCR upon oligomycin, which removes ATP synthase activity while leaving non-mitochondrial oxygen consumption unchanged:\n$$\n\\text{ATP-linked respiration} = B - O = 130 - 79 = 51.\n$$\n\n3. Spare respiratory capacity equals the difference between maximal mitochondrial respiration and basal mitochondrial respiration. Since both maximal and basal are corrected by subtracting the same non-mitochondrial oxygen consumption $N$, this is equivalently the difference between the FCCP and basal means:\n$$\n\\text{Spare capacity} = (F - N) - (B - N) = F - B = 207.\\overline{6} - 130 = 77.\\overline{6}.\n$$\n\nConvert each to scientific notation and round to three significant figures:\n\n- Basal mitochondrial respiration: $110 = 1.10 \\times 10^{2}$.\n- ATP-linked respiration: $51 = 5.10 \\times 10^{1}$.\n- Spare respiratory capacity: $77.\\overline{6} \\approx 77.7 = 7.77 \\times 10^{1}$.\n\nThese values are expressed per $10^{5}$ cells in $\\mathrm{pmol\\ O_{2}\\ min^{-1}}$ as specified.", "answer": "$$\\boxed{\\begin{pmatrix}1.10 \\times 10^{2} & 5.10 \\times 10^{1} & 7.77 \\times 10^{1}\\end{pmatrix}}$$", "id": "2868684"}, {"introduction": "Beyond measuring overall metabolic rates, a deeper understanding of metabolic reprogramming requires us to map the precise routes that nutrients travel within the cell. This advanced practice introduces stable isotope tracing, a powerful method for tracking the fate of atoms through intricate metabolic networks. You will act as a metabolic detective, using mass spectrometry data from $^{13}C$-labeled glutamine to quantify the activity of a non-canonical pathway—reductive carboxylation—in hypoxic T cells. Solving this problem will illuminate how T cells rewire their central carbon metabolism to adapt to challenging environments and will hone your skills in interpreting fluxomics data [@problem_id:2868615].", "problem": "Activated T lymphocytes exposed to low oxygen tension undergo metabolic reprogramming that alters tricarboxylic acid (TCA) cycle routing. Consider an experiment in which activated T cells are incubated under hypoxia for a short labeling period with uniformly labeled glutamine, denoted [U-$^{13}$C]glutamine (that is, all five carbons of glutamine are $^{13}$C), while glucose and dissolved inorganic carbon ($\\text{CO}_2/\\text{HCO}_3^-$) are unlabeled. Under hypoxia, pyruvate dehydrogenase (PDH) activity is negligible, so acetyl coenzyme A (acetyl-CoA) supplying the TCA cycle is effectively unlabeled during the pulse. Natural abundance corrections have been applied to all isotopologue measurements. The measured mass isotopologue distribution (MID) of citrate after the pulse is: $f_{M+0} = 0.58$, $f_{M+4} = 0.19$, $f_{M+5} = 0.23$, and $f_{M+k} = 0$ for all other $k$. Assume that the observed citrate pool is a mixture of a pre-existing unlabeled pool and newly synthesized citrate molecules formed during the labeling period. Using only foundational carbon accounting for the oxidative TCA cycle and the isocitrate dehydrogenase (IDH)-mediated reductive carboxylation of $\\alpha$-ketoglutarate, infer the fraction (as a decimal between $0$ and $1$) of newly synthesized citrate molecules that arose via reductive carboxylation during the labeling interval. Express your answer as a decimal fraction and round your answer to four significant figures.", "solution": "The problem is first subjected to validation.\n\n**Step 1: Extract Givens**\n- **System:** Activated T lymphocytes under hypoxia.\n- **Labeled Substrate:** Uniformly labeled glutamine, [U-$^{13}$C]glutamine ($5$ carbons are $^{13}$C).\n- **Unlabeled Substrates:** Glucose, dissolved inorganic carbon ($\\text{CO}_2/\\text{HCO}_3^-$).\n- **Condition:** Pyruvate dehydrogenase (PDH) activity is negligible.\n- **Consequence:** Acetyl coenzyme A (acetyl-CoA) is effectively unlabeled ($M+0$).\n- **Data:** Measured mass isotopologue distribution (MID) of citrate, corrected for natural abundance: $f_{M+0} = 0.58$, $f_{M+4} = 0.19$, $f_{M+5} = 0.23$, and $f_{M+k} = 0$ for all other $k$.\n- **Assumption:** The total citrate pool is a mixture of a pre-existing unlabeled pool and newly synthesized citrate.\n- **Pathways:** Oxidative tricarboxylic acid (TCA) cycle and isocitrate dehydrogenase (IDH)-mediated reductive carboxylation of $\\alpha$-ketoglutarate.\n- **Objective:** Calculate the fraction of newly synthesized citrate that arose via reductive carboxylation, rounded to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, describing a standard $^{13}$C metabolic flux analysis experiment in immunology. The stated conditions (hypoxia, negligible PDH activity) and pathways (reductive carboxylation) are well-established phenomena in cancer and immune cell metabolism. The problem is well-posed, providing sufficient quantitative data ($f_{M+k}$) and clear biochemical constraints to deduce the requested fraction. The language is objective and precise. The problem does not violate any criteria for invalidity.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived.\n\n**Derivation of Solution**\nThe problem requires tracing the carbon atoms from [U-$^{13}$C]glutamine to citrate through two distinct metabolic routes. Let $M+k$ denote a molecule (isotopologue) containing $k$ atoms of $^{13}$C in excess of natural abundance.\n\n1.  **Carbon Tracing for the Oxidative Pathway**\n    The starting labeled substrate is [U-$^{13}$C]glutamine, which has $5$ carbons, all labeled. This is a $M+5$ species. Glutamine is converted to glutamate and then to $\\alpha$-ketoglutarate (AKG) without loss of carbon atoms. Therefore, the resulting AKG is also fully labeled, an AKG $M+5$ isotopologue.\n    In the oxidative TCA cycle, the $5$-carbon AKG ($M+5$) is decarboxylated by the AKG dehydrogenase complex to form $4$-carbon succinyl-CoA. This reaction releases one molecule of $\\text{CO}_2$. Since the AKG is fully labeled, the released CO$_2$ is $^{13}\\text{CO}_2$, and one labeled carbon is lost. The resulting succinyl-CoA is therefore an $M+4$ species.\n    The subsequent steps of the TCA cycle (succinyl-CoA $\\rightarrow$ succinate $\\rightarrow$ fumarate $\\rightarrow$ malate $\\rightarrow$ oxaloacetate) are a series of conversions on a $4$-carbon backbone. No further carbon atoms are lost or gained. Thus, the oxaloacetate (OAA) formed at the end of this sequence is an $M+4$ species.\n    Finally, citrate is formed by the condensation of this OAA($M+4$) with acetyl-CoA. The problem states that PDH activity is negligible, so glucose does not contribute to the acetyl-CoA pool, which is considered unlabeled ($M+0$). The reaction catalyzed by citrate synthase is:\n    $$ \\text{OAA}(M+4) + \\text{Acetyl-CoA}(M+0) \\rightarrow \\text{Citrate}(M+4) $$\n    Thus, the oxidative pathway exclusively produces citrate $M+4$.\n\n2.  **Carbon Tracing for the Reductive Pathway**\n    This pathway also starts with AKG($M+5$) derived from labeled glutamine. The enzyme isocitrate dehydrogenase (IDH), operating in the reverse (reductive) direction, catalyzes the carboxylation of AKG to form isocitrate. The source of the additional carbon is the unlabeled pool of dissolved $\\text{CO}_2/\\text{HCO}_3^-$. The reaction is:\n    $$ \\text{AKG}(M+5) + \\text{CO}_2(M+0) + \\text{NADPH} \\rightarrow \\text{Isocitrate}(M+5) + \\text{NADP}^+ $$\n    The resulting $6$-carbon isocitrate molecule contains the $5$ labeled carbons from AKG and $1$ unlabeled carbon from CO$_2$, making it an $M+5$ species. Isocitrate is in rapid equilibrium with citrate via the enzyme aconitase. Therefore, the reductive pathway exclusively produces citrate $M+5$.\n\n3.  **Quantitative Analysis of the Citrate Pool**\n    The observed citrate pool is a mixture. Let $f_{new}$ be the fraction of the total citrate pool that is newly synthesized during the labeling period. The remainder, $1 - f_{new}$, is the fraction of pre-existing, unlabeled citrate.\n    The newly synthesized citrate is composed of molecules from the oxidative pathway ($M+4$) and the reductive pathway ($M+5$). The measured MID shows that the only labeled species are $M+4$ and $M+5$. Therefore, the total fraction of newly synthesized citrate is the sum of their fractional abundances:\n    $$ f_{new} = f_{M+4} + f_{M+5} $$\n    Substituting the given values:\n    $$ f_{new} = 0.19 + 0.23 = 0.42 $$\n    This implies that $42\\%$ of the total citrate pool was synthesized during the labeling period. The remaining fraction is $1 - f_{new} = 1 - 0.42 = 0.58$, which is entirely unlabeled ($M+0$). This calculated value matches the given $f_{M+0} = 0.58$, confirming the consistency of the model.\n\n    The problem asks for the fraction of *newly synthesized* citrate that arose via reductive carboxylation. Let this fraction be $r$. By definition, this is the ratio of the amount of citrate produced via the reductive path to the total amount of newly synthesized citrate. Using the fractional abundances from the MID as a measure of these amounts:\n    $$ r = \\frac{\\text{Abundance of reductively synthesized citrate}}{\\text{Total abundance of newly synthesized citrate}} $$\n    The reductively synthesized citrate is the $M+5$ species, and the total newly synthesized pool consists of the $M+4$ and $M+5$ species.\n    $$ r = \\frac{f_{M+5}}{f_{M+4} + f_{M+5}} $$\n    Substituting the numerical values:\n    $$ r = \\frac{0.23}{0.19 + 0.23} = \\frac{0.23}{0.42} $$\n    Calculating the value:\n    $$ r \\approx 0.5476190... $$\n    The problem requires the answer to be rounded to four significant figures.\n    $$ r \\approx 0.5476 $$", "answer": "$$\\boxed{0.5476}$$", "id": "2868615"}]}